News and Media

Videos

Press Releases

Sept. 10, 2019

FDA Grants Breakthrough Device Designation to LAM’S Novel Liver Cancer Detection Test

Sept. 10, 2019 — The breakthrough device designation will enable the company to streamline its development process and make novel approach easily accessible to doctors and patients.

Read More

Sept. 6, 2019

In Brief This Week: Laboratory for Advanced Medicine, Prescient Metabiomics, Precipio, and More

Sept. 6, 2019 — The U.S. Food and Drug Administration (FDA) has granted a Breakthrough Device designation to a Liquid Biopsy Liver Cancer Detection Test being developed by Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company.

Read More

Sept. 6, 2019

FDA Grants Breakthrough Device Designation to Liquid Biopsy Liver Cancer Detection Test

Sept. 6, 2019 — The U.S. Food and Drug Administration (FDA) has granted a Breakthrough Device designation to a Liquid Biopsy Liver Cancer Detection Test being developed by Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company.

Read More

Sept. 4, 2019

Laboratory for Advanced Medicine’s liver cancer test gets FDA breakthrough tag

Sept. 4, 2019 — If validated in further assessments, that finding would suggest the diagnostic can identify patients with tumors that are hard to detect using existing screening methods.

Read More

Sept. 4, 2019

LAM Gets FDA Breakthrough Designation for Liver Cancer Liquid Biopsy

Sept. 4, 2019 — “This non-invasive way of uncovering the earliest signs of malignancy is attractive to both providers of healthcare services and patients alike,” said Jinjie Hu, Laboratory for Advanced Medicine’s Chief Regulatory Officer.

Read More

Sept. 3, 2019

Liver-Cancer Detection Test Gets Breakthrough Device Status

Sept. 3, 2019 — “The new liver cancer detection test has a low false negative and false positive rate. Over 700,000 patients are at increased risk for liver cancer in the United States, and there is a 15-fold increase in five-year survival rates when the cancer is detected at early stages versus late stages.”

Read More

Mar. 20, 2019

LAM To Present Data For Cell-Free DNA Methylation Assay For Non-Invasive Diagnosis Of Liver, Breast And Colorectal Cancers At AACR Annual Meeting 2019

IRVINE, Calif., Mar. 20, 2019 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, announced today a poster presentation titled “Circulating Cell-Free DNA Methylation Assay: Towards Early Detection of Multiple Cancer Types” will be presented at the American Association for Cancer Research (AACR) Annual Meeting.

Read More

Dec. 7, 2018

Laboratory For Advanced Medicine Announces New Data Demonstrating High Diagnostic Potential Of DNA Methylation-Based Biomarkers For Early And Noninvasive Diagnosis Of Breast Cancer At San Antonio Breast Cancer Symposium

IRVINE, Calif., Dec. 7, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced new data at the San Antonio Breast Cancer Symposium validating results from its discovery of biomarkers to accurately detect breast cancer.

Read More

N0v. 20, 2018

LAM To Present Data Demonstrating Efficacy Of DNA Methylation As Epigenetic Biomarkers For Non-Invasive Breast Cancer Detection At Upcoming San Antonio Breast Cancer Symposium

IRVINE, Calif., Nov. 20, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced the title of its abstract to be presented at the 2018 San Antonio Breast Cancer Symposium taking place Dec. 4 – 8 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

Read More

Nov. 6, 2018

LAM Announces New Data Validating High Sensitivity And Specificity Of DNA Methylation-Based Biomarkers For Noninvasive Diagnosis Of Liver Cancer At SITC Meeting

Biomarkers demonstrate 95% sensitivity and 97.5% specificity in diagnosing hepatocellular carcinoma IRVINE, Calif., Nov. 6, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced new data further validating results from its completed clinical study…

Read More

Oct. 23, 2018

LAM Announces Presentation Of DNA Methylation-Based Biomarker Data For Noninvasive Diagnosis Of Hepatocellular Carcinoma At SITC 2018

IRVINE, Calif., Oct. 23, 2018 — Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, today announced the title of its abstract to be presented at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting taking place…

Read More

Jul. 12, 2018

Laboratory For Advanced Medicine Appoints Jinjie Hu As Chief Regulatory Officer 

IRVINE, Calif., July 12, 2018 — Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company focused on developing innovative technologies for the early diagnosis and intervention of cancers, today announced that the Company has recently appointed Dr. Jinjie Hu as its Chief Regulatory Officer. Dr. Hu has over a…

Read More

Jun. 4, 2018

Laboratory For Advanced Medicine To Present At 2018 BIO International Convention

IRVINE, Calif., June 4, 2018 — Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company developing innovative technologies for the early diagnosis and intervention of cancers, today announced that Justin Li, General Manager and Vice President of Finance, will present at the 2018 BIO International Convention, taking place on…

Read More

May 30, 2018

Laboratory For Advanced Medicine Commercializes Non-Invasive, Artificial Intelligence-Based IvyGene Blood Test For Cancer Detection

IRVINE, Calif., May 30, 2018 — Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company developing innovative technologies for the early diagnosis and intervention of cancers, today announced the commercialization of its revolutionary, non-invasive and highly accurate IvyGene test. IvyGene is designed to detect DNA methylation patterns consistent with…

Read More

May 17, 2018

Laboratory For Advanced Medicine Appoints Richard Brand As Chief Financial Officer

IRVINE, Calif., May 17, 2018 — Laboratory for Advanced Medicine (LAM), a clinical-stage medical technology company focused on developing innovative technologies for the early diagnosis and intervention of cancers, today announced that the Company has appointed Richard Brand as its Chief Financial Officer, effective immediately. Mr. Brand has more than…

Read More

Mar. 14, 2018

Firefighters Against Cancer And Exposures (FACES) Non-Profit Launches In Texas

IRVINE, Calif., March 14, 2018 — In an effort to help firefighters cover the high cost of cancer treatment as a result of the occupational risk of experiencing higher rates of certain types of cancer than the general U.S. population, Laboratory for Advanced Medicine (LAM) today announced the launch of…

Read More

Close Menu
Call Now Button